Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Singapore
  4. Singapore Stock Exchange
  5. The Trendlines Group Ltd.
  6. News
  7. Summary
    42T   IL0011328858

THE TRENDLINES GROUP LTD.

(42T)
  Report
Delayed Singapore Stock Exchange  -  01:38 2022-12-01 am EST
0.0880 SGD   -6.38%
11/17Saturas Ltd. announced that it expects to receive $0.7 million in funding from Agriline Ltd., The Trendlines Group Ltd.
CI
11/17Escala Medical announced that it has received $0.672 million in funding from Agriline Ltd., The Trendlines Group Ltd.
CI
11/17Limaca Medical Ltd announced that it expects to receive $0.35 million in funding from The Trendlines Group Ltd., Agriline Ltd.
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Trendlines : CoreBone Raises $3.7 Million Investment to Commercialize its Bioactive Bone Graft Material for Dental and Orthopedic Treatments & Expand Activity in China

10/04/2021 | 08:08am EST

CoreBone, a company that produces bioactive, coral-based bone graft material, announced that it has completed an investment round of $3.7 million. The Guangzhou Sino-Israel Biotech Investment Fund ("GIBF"), which focuses on introducing Israeli medical technologies to the Chinese market, invested $3 million in CoreBone's Chinese subsidiary; The Trendlines Group and Agriline (a trust of which Vincent Tchenguiz is a discretionary beneficiary) invested $700,000. The funds will be used for extending CoreBone's commercial global presence, primarily in China, which is the world's fastest growing market.

CoreBone develops and sells bioactive bone graft material for dental and orthopedic indications. It is the only company that uses cultured coral for bone grafting. Corals are grown on Moshav Ein Yahav in the south of Israel, in a closed, controlled aquatic (aquarium) system using proprietary technology and laboratory-made sea water enriched with bioactive nutrients and CoreBone's own coral breeding source. The coral has similar properties to human or animal bones and replaces the need for using animal or human bone for bone grafting. This eliminates the risk of disease transfer associated with these products. In China, the import of foreign human-derived bone grafts is banned - creating a tremendous growth opportunity for CoreBone's products.

Commenting on the investment, CoreBone CEO Ohad Schwartz said,

This investment in CoreBone will accelerate our sales efforts in China. CoreBone's graft material provides all the required bone formation qualities and more, without the limitations associated with animal or human sources. We are excited to bring this alternative technology to the bone graft market worldwide.

Prof. Shlomo Noy, GIB's Managing Partner and Chief Medical Officer, said:

CoreBone's Chinese subsidiary started in the technological incubator that our group is managing in Guangzhou according to the principles of the renowned Israeli incubation system. The current subsequent investment by our fund is therefore another great example for our unique success in bringing Israeli companies to China, while protecting their IP and maintaining their own control and management over the Chinese subsidiary. During the incubation period, we had a chance to work closely with CoreBone's team and to make significant progress towards Chinese regulatory approval for its unique products. We are confident that CoreBone will be successful in fulfilling the great unmet medical need it is targeting, partly by our unique capability to perform clinical trials in China.

Disclaimer

Trendlines Group Ltd. published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2021 12:01:50 UTC.


ę Publicnow 2021
All news about THE TRENDLINES GROUP LTD.
11/17Saturas Ltd. announced that it expects to receive $0.7 million in funding from Agriline..
CI
11/17Escala Medical announced that it has received $0.672 million in funding from Agriline L..
CI
11/17Limaca Medical Ltd announced that it expects to receive $0.35 million in funding from T..
CI
11/07Celleste Bio announced that it has received funding from The Trendlines Group Ltd., Mon..
CI
10/21Singapore Stocks End Week with Losses; Soilbuild Construction Shares Soar 23% on Secur..
MT
10/21Trendlines Group Places Over 21 Million Shares to Four Investors; Shares Drop 3%
MT
09/14GreenSpense Ltd. announced that it expects to receive $0.4 million in funding from The ..
CI
09/14Sol-Chip Ltd. announced that it expects to receive $0.25 million in funding from Agrili..
CI
08/11The Trendlines Group Ltd. Appoints Low Teck Seng as an Independent and Non-Executive Di..
CI
08/11Transcript : The Trendlines Group Ltd., H1 2022 Earnings Call, Aug 11, 2022
CI
More news
Financials (USD)
Sales 2021 16,1 M - -
Net income 2021 6,56 M - -
Net cash 2021 8,45 M - -
P/E ratio 2021 12,8x
Yield 2021 -
Capitalization 60,1 M 60,1 M -
EV / Sales 2020 -17,4x
EV / Sales 2021 3,33x
Nbr of Employees 53
Free-Float 19,3%
Chart THE TRENDLINES GROUP LTD.
Duration : Period :
The Trendlines Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE TRENDLINES GROUP LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
D. Todd Dollinger Co-Chairman & Co-Chief Executive Officer
Steve Rhodes Co-Chairman & Co-Chief Executive Officer
Haim Brosh CFO, Joint Secretary & Compliance Officer
Shahar Harari Chief Technology Officer
Irit Shemesh Catz Operations Director
Sector and Competitors
1st jan.Capi. (M$)
THE TRENDLINES GROUP LTD.-16.98%60
BLACKROCK, INC.-21.12%107 540
BROOKFIELD ASSET MANAGEMENT INC.-16.98%73 747
BLACKSTONE INC.-34.28%64 234
UBS GROUP AG4.90%57 700
KKR & CO. INC.-30.31%44 709